Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
133
resultados
Última actualización
09/08/2025 [07:00:00]
Resumen de: US2025249170A1
A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to PWD designated assistance entities (e.g., family, friends, givers, HCPs, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the PWD will immediately perform the designated maintenance task. In some cases, methods, devices, and systems provided herein can use proximity to non-paired mobile computing devices to deliver data to PWD designated assistance entities.
Resumen de: US2025248666A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: US2025248667A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: US2025248633A1
Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a sensor configured to generate a signal associated with a concentration of an analyte; and a sensing membrane located over the sensor. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.
Resumen de: US2025248627A1
Provided is an implant apparatus for a continuous glucose monitor. The implant apparatus includes a housing assembly and a driving assembly disposed in the housing assembly. The housing assembly includes an outer housing. The outer housing has an opening at an end of the outer housing. The driving assembly has a locked state in which the driving assembly is fixed relative to the outer housing and a triggered state in which the driving assembly is movable towards the opening. The implant apparatus further includes a trigger. The outer housing includes a guiding channel located at a side wall of the outer housing and extending towards the opening. The trigger is movable along the guiding channel towards the opening and has a first position and a second position relative to the outer housing, to enable the driving assembly to switch from the locked state to the triggered state.
Resumen de: US2025248654A1
Embodiments of the invention provide skin adhesive patches designed to ease a diabetic patient's maneuverability and alignment of a glucose sensing device as the patient adheres the device to their skin. Embodiments of the invention can be adapted for use with a wide variety of medical components that are coupled to the skin of patients, including insulin infusion sets, patch pumps, and all-in-one patch sets.
Resumen de: US2025248624A1
The present invention relates to a system and method for predicting blood glucose levels in a non-invasive manner using deduction learning. The deduction learning (DL) model 10 of the present invention predicts blood glucose level 300 based on the relationship or correlation between blood glucose level variation and PPG signal variation. Specifically, the DL model 10 of the present invention comprises a differential cell 100 (DC) configured to calculate predicted blood glucose level BGpred 300 using two PPG signals Si 200b and Si−1 200a, a BG i−1,ref 230 and relationship or correlation between variances of the two PPG signals and variances of the reference blood glucose level 230 and the predicted blood glucose level 300.
Resumen de: US2025249171A1
A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to PWD designated assistance entities (e.g., family, friends, givers, HCPs, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the PWD will immediately perform the designated maintenance task. In some cases, methods, devices, and systems provided herein can use proximity to non-paired mobile computing devices to deliver data to PWD designated assistance entities.
Resumen de: US2025253045A1
A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment for tube-fed patients from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.
Resumen de: MX2025008037A
Systems and methods for monitoring glucose variability are described. Data indicative of glucose levels of the subject is received. A first glucose metric is determined in a first time period. A second glucose metric is determined in a second time period. A difference between the second and first glucose metrics are determined. The difference is compared to a threshold. A first indicator is displayed if the difference does not exceed the threshold and a second indicator is displayed if the difference exceeds the threshold. In some embodiments, the indicator is one of a balanced state or a steady state and the second indicator is one of an unbalanced state, an unsteady state, a not steady state, or a spiky state.
Resumen de: US2025241561A1
A non-invasive glucose sensor used for glucose detection in a subject is provided. The sensor includes a long channel source to excite a first location of a skin and a long channel detector to detect near infrared (NIR) energy emitted from the first location of the skin. A short channel source excites a second location of the skin and a short channel detector detects NIR energy emitted from the second location of the skin. The sensor further includes a long channel processor to process a long channel electrical signal into a glucose spectroscopic data and a short channel processor to process a short channel electrical signal into a background spectroscopic data. The sensor includes a spectroscopic processor to subtract the background spectroscopic data from the glucose spectroscopic data, and thereby to produce data indicative of a quantity of glucose present in the subject's blood.
Resumen de: US2025241598A1
Method and apparatus for receiving a first signal indicative of first glucose levels measured by a first working electrode, receiving a second signal indicative of second glucose levels measured by a second working electrode, detecting a first decrease in an amplitude of the first signal measured by the first working electrode that exceeds a first threshold, detecting a second decrease in an amplitude of the second signal measured by the second working electrode that exceeds the first threshold, selecting the first signal based on determining that the first decrease in the amplitude of the first signal is less than the second decrease in the amplitude of the second signal, determining a rate of change corresponding to the first decrease in the amplitude of the first signal, comparing the rate of change to a second threshold, confirming, based on the comparison, that the first signal is valid.
Resumen de: WO2025159222A1
The present disclosure relates to a method and a device for predicting the risk of gestational diabetes by using an artificial intelligence model. An embodiment of the present disclosure may provide a method for predicting the risk of gestational diabetes by using an artificial intelligence model, the method comprising the steps of: inputting data on a mother to a gestational diabetes prediction model generated on the basis of a training data set; and obtaining the incidence rate of gestational diabetes from the gestational diabetes prediction model, wherein the data on the mother includes a final variable determined from multiple initial variables of the training data set.
Resumen de: WO2025157775A1
The present invention relates to a method for obtaining at least one item of nail information on at least one nail (130) of a living being by at least one spectroscopic measurement, the method comprising: i. acquiring spectral information by using at least one spectrometer device (124) at one or more different measurement position; ii. acquiring at least one item of reference information on at least one reference position by using at least one reference position measurement unit (136); and iii. evaluating the spectral information for obtaining the at least one item of nail information on the at least one nail (130), wherein, by evaluating the at least one item of reference information on the at least one reference position when evaluating the spectral information, the measurement position for any item of nail information on the at least one nail (130) is obtained.
Resumen de: US2025246285A1
Techniques, systems and devices for glycemic control are presented. An apparatus may include a display device and a processor in electronic communication with the display device. The apparatus includes a memory communicatively connected to the processor. The memory includes instructions configuring the processor to generate a user interface through the display device and receive user input through the user interface. The processor is configured to implement an activity mode of a plurality of activity modes of a wearable medical device based on the user input. The activity mode is indicative of temporary conditions affecting blood glucose levels of the user. The processor is configured to receive biological data from a user through a biological sensor in communication with the processor and calculate an amount of medication to deliver to a user based on the biological data and the implemented activity mode.
Resumen de: AU2023415722A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: AU2025205479A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated. Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated. ul y s t e m s a n d m e t h o d s f o r i n t e g r a t i n g a c o n t i n u o u s g l u c o s e s e n s o r , i n c l u d i n g a u l r e c e i v e r , a m e d i c a m e n t d e l i v e r y d e v i c e , a c o n t r o l l e r m o d u l e , a n d o p t i o n a l l y a s i n g l e p o i n t g l u c o s e m o n i t o r a r e p r o v i d e d n t e g r a t i o n m a y b e m a n u a l , s e m i - a u t o m a t e d a n d o r f u l l y a u t o m a t e d
Resumen de: WO2025159993A1
Disclosed herein is a healthcare management system and method utilizing machine learning based predictive analytics to improve patient adherence rates for chronic care management (e.g., diabetes). An example system may include a computing device configured to establish a customer analytical record to synthetize over a plurality of selected attributes to form a patient centric view of patient behaviors, attitude, characteristics based upon data related to chronic disease state management and social determinants of health, consumer experience to determine, using a predictive artificial intelligence model, a patient's predictive adherence for next 1-3 months, and determine tailored intervention plans to engage patients for continuing adherence.
Resumen de: WO2025160068A1
An analyte assessment system includes an analyte sensor, a remote device, and a software application. The remote device is configured to retrieve sensor data of a patient from the analyte sensor. The software application is configured to receive an order for analyte assessment associated with an electronic medical record (EMR) of the patient, generate or retrieve a unique identifier associated with the order, authenticate the unique identifier with the remote device, activate the analyte sensor based on the unique identifier, retrieve sensor data from the remote device, generate a report, and upload the report to the EMR of the patient. Advantageously the system can streamline requests and delivery of analyte reports for third parties, reduce in-person patient interactions and time delays, reduce third party effort, increase security and integrity of patient data, update an EMR of the patient, and operate in a blinded mode for unbiased patient analyte assessment.
Resumen de: EP4591791A2
The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: EP4592427A2
An apparatus includes a body and an actuator is coupled to the body. A needle is mounted to the actuator. The needle comprises a slot along a length to a tip. A sensor is coupled to a plurality of wires. A base is configured to be moveable by the actuator and includes a cutout, a circuit board having a microprocessor, and a plurality of contacts. Each contact is coupled to a wire of the plurality of wires. A power source is connected to the circuit board and to the base. A bracket is coupled to the bottom surface of the body and configured to receive the base. A patch is coupled to the bracket and has an adhesive. A needle is configured to be moveable by the actuator. The plurality of wires extend from the circuit board of the base, through the needle and out of the slot.
Resumen de: AU2025205069A1
MARKED-UP COPY The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data. The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between
Resumen de: AU2024209583A1
The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.
Resumen de: AU2023420510A1
Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.
Nº publicación: US2025239350A1 24/07/2025
Solicitante:
CURESTREAM CO LTD [KR]
POSTECH RES AND BUSINESS DEVELOPMENT FOUNDATION [KR]
CureStream Co.,Ltd,
POSTECH Research and Business Development Foundation
Resumen de: US2025239350A1
Provided is a personalized artificial intelligence-based insulin dose determination system includes an interface layer capable of communicating with the insulin pump and the continuous blood glucose system, and signal-processing information from the insulin pump and the continuous blood glucose system, a control layer receiving the signal-processed information from the interface layer and generating output information associated with an insulin infusion amount, an outer safety layer determining whether or not the output information generated from the control layer satisfies a preset threshold condition, and delivering the output information to the interface layer when the output information satisfies the preset threshold condition, and a personalized safety layer receiving prescription information including Total Daily Dose of Insulin (TDD) information of the user from the outside to determine a personalized safety control variable, and transmitting the determined control variable as an input variable of the control layer.
BOPI
Sede Electrónica
